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Abstract 
Background and Aim: Prostate cancer (PCa) is the leading cancer diagnosis amongst South 
African men. The incidence of PCa is 68.0 per 100 000 Age Standardized Rate (ASR) and the 
mortality rates are 27.9 per 100 000 ASR, Globocan 2018. Diagnosis of PCa is based on a 
combination of digital rectal examination, prostate-specific antigen (PSA) and histology. 
Several biomarkers have been used to increase the sensitivity and specificity of PSA in 
distinguishing patients with PCa from those with benign prostatic hyperplasia (BPH). These 
include fractionated PSA, free/total PSA ratio, −2proPSA, prostate cancer antigen 3 and 
prostate health index, amongst others. Biomarkers are needed to differentiate BPH from PCa 
due to a lack of specificity of these markers with PSA levels above 4.0 ng/ml. The aim of this 
study is to investigate gene expression patterns of South African men in 9 PCa and 10 BPH 
patients in order to distinguish between the two groups.  
Methods: Ethical approval was obtained (HREC 454/2012). Patients scheduled for 
transurethral resection of the prostate were recruited from the Western Cape. RNA was 
extracted from prostate tissue using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen). 
Complementary DNA was synthesized from RNA using the SuperScript IV VILO Master Mix 
(Thermo Fischer Scientific). Gene expression was analyzed with the Human Prostate Cancer 
RT2 Profiler PCR Array and SYBR Green Master Mix. Data were analyzed with the 
GeneGlobe RT2 and miScript PCR Array Data Analysis Centre from Qiagen.  
Results: The cohort included patients from different ethnic groups namely, Caucasians, Mixed- 
and African ancestry. The PCa group has an age range from 56 to 75 years (mean 65) while 
the BPH group was slight older ranging from 60 to 76 years (mean 68). PSA levels range from 
24 to 5000 ng/ml (mean 1252 ng/ml, median 185) for the PCa group and 11 to 58 ng/mL (mean 
25 ng/ml, median 22) for the BPH group. The following genes were downregulated 2-fold in 
the PCa group with p values <0.05, IGF1, PTEN, GSTP1, SOCS3, EGR3, GPX3, TIMP3, 
ZNF185, DKK3, PTGS2, FOXO1, ARNTL, TNFRSF10D, CCND1, and DLC1, upregulated 
genes included CDH1, MKI67, TMPRSS2, ERG, CDKN2A, FASN, and AR but were not 
statistically significant. At a fold-change threshold of 1.5, the following additional genes were 
downregulated in the PCa group with p values <0.05, DAXX, EGFR, RASSF1, SOX4, and 
TIMP2, upregulated genes were ACACA, AR, CDKN2A, ERG and FASN but were also not 
statistically significant. The study shows similarly differentially expressed genes as seen in 
international studies. Of note PTEN, MKI67 and FASN which are associated with poor 
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prognosis. EGR3 was downregulated in our study and this has been associated aggressive 
disease and predict relapse after PCa treatment. This could explain the high mortality 
demonstrated in South African epidemiological studies. 
Conclusion: We identified a group of differentially expressed genes that have potential in 
distinguishing PCa and BPH patients with PSA values above 10 ng/ml. A larger population 
study is needed to further evaluate the clinical significance of our findings. 
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Chapter 1. Introduction and Literature review 
1.1. Introduction: Prostate Cancer in South Africa 
Prostate cancer (PCa) is the second most common non-cutaneous malignancy diagnosed in 
men, following lung malignancy. It is the fifth leading cause of cancer death in men worldwide 
[1]. Similar (high) PCa incidences are reported in America, Europe and some parts of Sub-
Saharan Africa, however, the mortality rates reported in America and Europe are low compared 
to Sub-Saharan regions (South Africa, Zambia and Zimbabwe) and the Caribbean (Barbados, 
Jamaica, and Haiti), Figure 1. PCa incidences vary by race or ethnicity. African Americans 
have 59% higher incidence rates than Caucasian Americans [2]. Mortality rates are generally 
higher in African populations [Caribbean, 12.3-48.0 per 100,000 Age Standardized Rate (ASR) 
and Sub-Saharan Africa, 14.0-36.3 per 100,000 ASR], intermediate in America (7.7-14.0 per 





Figure 1. Global maps presenting the estimated (a) the incidence of PCa and (b) age standardized mortality rates, 
2018 [1]. 
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PCa is the leading cancer diagnosis amongst South African men. According to the International 
Agency for Research on Cancer (IARC), Globocan 2018, 12 452 new cases were diagnosed in 
2018 [3]. The incidence of PCa is 68.0 per 100 000 ASR, and the mortality rates are 27.9 per 
100 000 ASR in South Africa [1]. Black South African men have been shown to have higher 
PSA values, higher clinical and pathological stages (Gleason score>7 and poorly differentiated 
tumors) at diagnosis [4, 5]. Reasons for these findings are thought to be multifactorial; these 
include delayed presentation, different health-seeking behaviors which may be cultural related, 
lack of screening practices and biological factors which are likely genetic [4, 5]. 
Higher mortality rates and incidence of PCa reported in populations of African descent (Sub-
Saharan Africa) makes the study of PCa genetics in South Africa imperative.  
1.2. PCa Diagnosis 
The diagnosis of PCa is based on a PSA level and DRE. Even a suspicious DRE has shown a 
positive predictive value of only 5 to 30% in patients with PSA values below 4ng/ml [6]. 
Histological verification is, therefore, necessary to confirm the diagnosis of adenocarcinoma 
on prostate biopsy cores. A prostate biopsy is an invasive procedure that may be associated 
with complications such as bleeding, urinary retention, prostatitis, fever and may require 
hospitalization. 
Prostatic acid phosphatase was the first biomarker used for the diagnosis of PCa. With the 
discovery of PSA, it was rapidly replaced because of its poor sensitivity for diagnosis and 
follow up of PCa [7]. PSA is a glycoprotein primarily produced by prostatic luminal epithelial 
cells and is expressed by both normal and neoplastic prostate tissue. Higher levels of PSA are 
seen in PCa patients. Serum PSA levels are used for screening and diagnosis of PCa, with a 
high sensitivity in predicting PCa but with a low specificity as a marker for PCa [8]. PSA is 
organ-specific but not cancer-specific, therefore, it may be elevated in benign prostatic 
hyperplasia (BPH), prostatitis and other non-malignant conditions. Upper limits of normal for 
PSA are regarded as 4 ng/ml, while levels above 4ng/ml are suspicious for malignancy [9]. For 
PSA levels between 4.0 and 10.0ng/ml, the positive predictive value is about 25% and nearly 
75% of cancers detected in this zone are all confined and potentially curable [10]. The serum 
PSA is more useful for determining the extent of PCa and assessing the response to PCa 
treatment. Although its use in screening still remains a controversial topic, it has been 
associated with early diagnosis and a 21% reduction in mortality on long term follow up studies 
[11]. BPH is a pathological process characterized by an increase in the number of epithelial 
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and stromal cells in the periurethral area of the prostate. Similar to PCa, BPH is usually 
associated with lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction. 
There is a strong association between serum PSA and prostate volume in men with BPH and 
the relationship depends on age [12].  Twenty-eight percent of men with a histological proven 
BPH have serum PSA’s above 4ng/ml [13]. Therefore, there is a significant overlap in serum 
PSA values between men with BPH and clinically localized PCa. Localized PCa may also 
coexist with BPH.  
1.3. Biomarkers for PCa diagnosis 
Several biomarkers have been shown to improve the sensitivity and specificity of PSA in the 
diagnosis of PCa. These include serum-, urine- and tissue-based biomarkers (Table 1). Some 
of these biomarkers can also be used to select for repeat biopsies in men with an elevated risk 
of PCa and a prior negative biopsy.  
1.3.1. Serum-based biomarkers 
Free/total PSA ratio, PSA kinetics, and other markers have been used to increase the sensitivity 
of PSA in diagnosing PCa. The free/total PSA ratio has shown a low sensitivity and specificity 
alone in diagnosing PCa, with a sensitivity of 70% in men with PSA between 4 and 10ng/ml 
[14]. PSA velocity (absolute annual increase in serum PSA in ng/ml/year) and PSA doubling 
time (the time in months for PSA level to double) have limited value in PCa diagnosis. 
Additional serum tests have also been used to improve the diagnostic accuracy of PSA for PCa. 
These tests include [-2]proPSA, prostate health index (PHI, total PSA, free PSA and [-
2]proPSA) and the 4 kallikrein score (total PSA, free PSA, intact PSA and human kallikrein-
related peptide 2). These markers have been shown to be the strongest predictors of PCa on 
initial or repeat biopsies compared to total PSA and %free PSA alone [15-17].  
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Table 1: Summary of currently available biomarkers for use in prostate cancer detection or stratification 
Name of test Marker Description Biomaterial Indication FDA Accuracy 
Serum-based biomarkers 
proPSA & Prostate 
Health Index 
Total PSA,  
fPSA,  
p2PSA 
Blood Serum Diagnosis/Prognosis Yes AUC 0.703 
Spec 16%  
Sens 95% 
4K score test Total PSA,  
fPSA,  
intact PSA,  
hK2 
Blood plasma Diagnosis/Prognosis No AUC 0.82 
Urine-based biomarkers 





Post-DRE urine Diagnosis: re-biopsy 
setting 
Yes AUC 0.68-0.87 
TMPRSS2-ERG TMPRSS2-ERG Post-DRE urine Diagnosis: re-biopsy 
setting 
No Sens 24.3-37%,  








Post DRE first 
void urine 
Diagnosis/Prognosis No AUC 0.88 





Diagnosis/Prognosis No Sens 91%,  
Spec 36%,  
NPV 94%,  
PPV 27%,  
AUC 0.76 
Tissue-based biomarkers 
ConfirmMDx DNA methylation of 




Diagnosis No NPV 96% 
Oncotype DX  12 cancer related genes,   
5 reference genes 
Prostate cancer 
tissue 
Prognosis No Not reported 




Prognosis No  Not reported 
Decipher 22 RNA biomarkers Prostate cancer 
tissue 
Prognosis No  AUC 0.79 
Abbreviations: 4K, four-kallikrein panel; TMPRSS2-ERG, transmembrane protease serine 2-ERG; hK2, human kallikrein 
peptidase 2; AUC, area under the curve; FDA, US Food and Drug Administration.  
 
Table compiled from [18] and [19] 
 
1.3.2. Urine-based biomarkers 
Several urine biomarkers also have the potential to improve the diagnostic accuracy of PCa, 
mainly to select men for a repeat biopsy after an initial negative biopsy. These markers include 
prostate cancer antigen 3 (PCA3), TMPRSS2-ERG fusion, SelectMDX, Mi (chigan) Prostate 
score (MiPS) and ExoDx (Table 1). PCA3 is a prostate-specific long non-coding RNA 
(lncRNA) biomarker that is detectable in urine sediments obtained after three strokes of a 
prostatic massage during DRE. TMPRSS2-ERG fusion, a fusion of the transmembrane protease 
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serine 2 (TMPRSS2) and the ERG gene are frequently detected in PCa. TMPRSS2-ERG fusion 
has been shown to be highly specific (93-99%) for predicting PCa and clinically significant 
PCa on biopsy [20, 21]. When detection of TMPRSS2-ERG fusion in urine is added to PCA3 
expression and serum PSA (MiPS), cancer prediction improves significantly [21].  The use of 
this marker in our African population is questionable because the frequency of TMPRSS2-ERG 
fusion in PCa has shown notable racial disparities, the highest prevalence in men of European 
ancestry (49%), followed by Asian (27%) and African ancestries (25%) [22]. A recent South 
African PCa study showed a frequency of only 13% for TMPRSS2-ERG fusion in tumors from 
Black South Africa men. Additionally, an inverse relation was found for the acquisition of 
TMPRSS2-ERG fusion with aggressive PCa [23].  
The SelectMDX test is similarly based on mRNA biomarker isolation from urine. HOXC6 and 
DLX1 mRNA levels were shown to be good predictors for the detection of high-grade PCa 
[24]. Currently, both the MiPS-score and ExoDx assay are considered experimental. Combined 
analysis of androgen-receptor gene (AR-CAG) repeat length, the percentage of promoter 
methylation (PPM) of genes glutathione-S-transferase P1 (GSTP1) and Ras associated domain 
family 1 isoform A (RASSF1A) have also been reported to increase the specificity of PSA in 
PCa diagnosis [25].  
1.3.3. Tissue-based biomarkers 
Dysregulated gene expression has also been associated with PCa, disease progression and 
potential to metastasis. α-Methylacyl coenzyme A racemase (AMACR) has also been shown to 
be overexpressed in PCa tissue samples [26]. Hypermethylation of numerous genes including 
glutathione-S-transferase π (GSTP1), adenomatous polyposis coli (APC), retinoic acid 
receptors beta 2 (RARβ2), and RAS is A (RASSF1A) have also been implicated in the 
development of PCa [27]. ConfirmMDx is indicated for men who have a documented history 
of a previous negative prostate biopsy result for cancer or cellular atypia suspicious for 
malignancy. ConfirmMDx uses the methylation status of three biomarkers (GSTP1, RASSF1, 
and APC) from prostatic tissue to help determine a patient’s chance for having PCa on a 
subsequent biopsy. ConfirmMDx epigenetic assay was found to be a significant and 
independent predictor of PCa in repeat biopsies in men with prior negative biopsies with a 
negative predictive value of 88% [28].    
Genetic abnormalities have also been associated with an increased risk of PCa and advanced 
disease. Mutations in the p53 gene are reported in about 10 to 20% and 60 to 90% for primary 
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and advanced prostate cancers, respectively [29, 30]. Germline mutation of the BRCA2 tumor 
suppressor gene substantially increases the lifetime risk of developing PCa. BRCA2-mutant 
tumors also exhibit an increased frequency of intraductal carcinoma (IDC), a pathology that 
predicts adverse outcomes in both familial and sporadic PCa. BRCA2-mutants in PCa are 
uniquely aggressive, they are associated with younger age of onset, higher rates of lymph node 
and distant metastasis, and increased mortality relative to sporadic compared to non-BRCA2-
mutant disease [31]. In a small South African study, a germline variation has been observed in 
African versus European patients, no pathogenic mutations were found in known high 
penetrance genes such as BRCA1, BRCA2, ATM, HOXB13 and CHK2 [32]. A higher tumor 
mutational burden and a frequent gain of the MYC gene was seen in treatment naïve, high-risk 
PCa in an African versus a European cohort [33]. 
1.3.4. Tissue-based prognostic markers 
Gene expression profiling has also been used for risk stratification in men with PCa. These 
assays include Prolaris (Myriad Genetics), Oncotype Dx (Genomic Health) and Decipher 
(Genomic Dx Biosciences). The Prolaris test measures the expression of 31 cell-cycle 
associated genes in biopsy derived PCa tissue. These genes include FOXM1, CDC20, CDKN3, 
CDC2, KIF11, KIAA0101, NUSAP1, CENPF, ASPM, BUB1B, RRM2, DLGAP5 and TK1 
amongst others. Cell cycle progression (CCP) score provides prognostic value in terms of 
progression and death from PCa [34]. Oncotype Dx Genomic Prostate Score (GPS) assay is an 
RNA-based test based on 12 carcinoma-associated genes and 5 reference genes that can be 
applied to carcinoma tissue in prostate biopsies to determine the aggressiveness of the 
carcinoma. The assay profiles multiple gene pathways involved in PCa to predict disease 
aggressiveness. These pathways include androgen signaling (AZGP1, FAM13C, KLK2, and 
SRD5A2), cellular organization (FLNC, GSN, GSTM2, and TPM2), stromal response (BGN, 
COL1A1, and SFRP4), cellular proliferation (TPX2) and 5 reference genes [35]. Decipher uses 
oligonucleotide microarrays to measure 22 RNA expression biomarkers, extracted from 
formalin fixed paraffin embedded (FFPE) prostate biopsy specimens, to derive a Decipher score 
and corresponding probability of clinical metastasis in patients with PCa. This genomic 
classifier includes the following genes LASP1, IQGAP3, NFIB, S1PR4, THBS2, ANO7, 
PCDH7, MYBPC1, EPPK1, TNFRSF1,9 and PBX1 amongst others [36].   
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1.4. Identification of Biomarkers in the South African context 
Only PSA, PCA3 and PHI are FDA approved for PCa diagnosis and management. Except for 
PSA, none of the other biomarkers are commercially available in our resource-constrained 
environment. As most biomarker studies are based on European and American populations, it 
is unclear whether these markers are applicable to South African men as they have not been 
validated in our population. 
The quality and quantity of cell-free RNA and DNA isolated from urine or plasma are low in 
comparison with that isolated from tissue. Prostate tissue models show greater benefit on 
analysis with findings very similar to those observed in non-invasive tissue samples, like 
urinary sediment cells (USC) and cell-free DNA from plasma [25]. For example, positive 
predictive values of diagnosing PCa in the combined analysis of GSTP1 + RASSF1A + AR-
CAG ≥ 25 repeats, with PSA ≥ 4 and PPM ≥20 reaching 87.0% and 90.8% in plasma and USC 
respectively. Negative predictive value 64.5% and 67.5% for plasma and USC respectively. 
Increased values were seen with PSA ≥10 [25]. Considering this, in our study RNA was 
isolated from prostate tissue samples.  
1.5. Conclusion 
PCa is a heterogeneous disease, ranging from indolent to highly lethal disease. Higher mortality 
rates and incidence of PCa reported in Sub-Saharan African makes the study of PCa genetics 
in South Africa imperative. The aims of this study are to describe gene expression patterns of 
84 key genes [Appendix 1] commonly involved in PCa and to distinguish patients with PCa 
from those with BPH with PSA values above 10ng/ml. BPH patients selected presented with 
high PSA values similar to patients with PCa. The 84 genes are part of a commercially available 
Human Prostate Cancer RT² Profiler PCR Array. The array represents genes involved in 
androgen receptor, PI3 kinase/AKT, and PTEN signaling, as well as the cell cycle and apoptotic 
pathways. Identification of patterns in RNA expression will aid in biomarker development in 
a South African context. The study is also likely to identify genetic biomarkers unique to our 
population and ethnic groups. 
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Chapter 2. Material and methods 
2.1. Study Design 
Descriptive study 
2.2. Ethics and Cohort description 
The study is part of an ongoing project titled “Novel Markers of Prostate Cancer using 
Proteomics, Genomics and Lipidomics Techniques: An important Tool for Early Cancer 
Diagnosis and Treatment monitoring Protocol”. Human research ethics committee approval 
was obtained from the University of Cape Town, Faculty of Health Sciences (HREC REF: 
454/2012).  
South African men treated at Groote Schuur, New Somerset and Eerste Rivier Hospital in the 
Western Cape, who were scheduled for transurethral resection of the prostate (TURP), were 
included. It should be noted that surgery was performed for medical reasons and not for 
research purposes. Only a small portion of the prostate chips from the TURP procedure was 
collected, the remainder were analyzed by the National Health Laboratory Services (NHLS) to 
ensure accurate diagnosis and staging of the patients. Inclusion criteria were patients with a 
histological diagnosis of PCa or BPH, patients scheduled for transurethral resection of the 
prostate or radical prostatectomy as part of their treatment plan and patients able and willing to 
participate voluntarily and give written informed consent. Exclusion criteria were patients who 
received treatment for PCa, in the form of chemotherapy, hormonal manipulation or radiation 
treatment, insufficient material for analysis and patients unable or unwilling to consent. 
Informed written consent for enrolment in the study was obtained by members of the 
International Centre of Genetic Engineering and Biotechnology (ICGEB) and qualified staff of 
the Urology team at Groote Schuur Hospital. Informed consent was taken in the patient’s own 
language or by using an interpreter to ensure a full understanding of enrolment in the study and 
to deal with concerns and questions that were raised by patients. Brief genetic counseling was 
also  provided to ensure patient understanding of the nature of the study and their participation. 
2.3. RNA Isolation and cDNA synthesis 
Prostate tissue collected for the experiments was immediately stabilized with the RNA 
stabilizing reagent, RNAlater and stored at -80 degrees Celsius (°C). After a histological 
confirmation by the NHLS of BPH or PCa (at least 80% cancer on a tissue chip), RNA was 
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extracted from 20mg of frozen prostate tissue using the AllPrep DNA/RNA/miRNA Universal 
Kit, this was done by following the manufacture's protocol. Tissue lysis was done in 600 µl 
lysis buffer (RLT Plus) with a TissueLyser LT (QIAGEN), using 2 stainless steel 4 mm beads 
operated for 25 minutes at 40 Hz. The homogenized lysate was then transferred to an AllPrep 
DNA Mini spin column. To elute RNA, 20 µl RNase-free water was added directly to the spin 
column membrane and centrifuged at ≥ 8000 x g for 1 minute, step repeated once, for a total 
of 40 µl RNase-free water per specimen. RNA was quantified using a NanoDrop (Thermo 
Scientific).  RNA quality was measured using ultraviolet–visible spectroscopy (agarose gel 
electrophoresis) which measures absorbance of a diluted RNA sample. The Beer-Lambert law 
equation expresses the relation between absorption and concentration of nucleic acids:   
A = ϵCl 
A = absorbance, ϵ = molar extinction coefficient [0.025(μg/ml) cm-1], C = concentration (in 
the units corresponding to ϵ) and l = light pathlength.  
To avoid RNase contamination, the specimens were handled with aseptic techniques and all 
surfaces were treated with RNaseZAP (SIGMA). Complementary DNA (cDNA) was 
synthesized from 1 µg of RNA using the reverse transcription synthesis kit, SuperScript IV 
VILO Master Mix (Thermo Fischer Scientific). To remove possible genomic DNA 
contamination, the RNA samples were treated with DNase enzyme that is part of the 
SuperScript IV VILO Master Mix kit. cDNA was stored at -80 °C.  
2.4. PCR Array and Data Analysis 
RT2 Profiler PCR Array (QIAGEN) is a complete system for pathway-focused gene expression 
analysis. RT2 Profiler PCR Arrays were done on a 96-well plate using Format F which is 
suitable for the real-time PCR Roche Light Cycler 480 machine. RT2 Profiler PCR Array 
analyzed 84 key genes involved in PCa, 5 housekeeping genes, a genomic DNA control, 3 
reverse-transcription controls, and 3 positive PCR controls. The plate outline is shown in 
Figure 2 and the genes and their descriptions are listed in Appendix 1. These genes are 
commonly involved in PCa development. The procedure was done following the manufacture's 
protocol, in short: The PCR component mix was prepared in a 15 ml tube to a final 
concentration of 1x RT2 SYBR Green Master Mix, 1x cDNA synthesis reaction (prepared from 
1 µg RNA) and RNase-free water to a total of 2.7mls. The RT2 Profiler PCR Array was tightly 
sealed with an optical adhesive film and centrifuged at 1000 x g for 1 minute at room 
temperature to remove bubbles. PCR cycling programs were as follows 1) heat activation for 
10 minutes at 95 °C, 1 cycle (ramp rate 4.8 °C/s), 2) quantification for 15 seconds at 95 °C 
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(ramp rate 1.5 °C/s) and 1 minute at 60 °C (ramp rate 1.5 °C/s), 45 cycles. The melting curves 
were obtained by decreasing the temperature to 60 °C before continuously increasing the 
temperature to 95 °C with a ramp rate of 0.03 °C/s. Data were captured and analyzed using a 
Second Derivative Maximum analysis method, this is an algorithm based on the kinetics of a 
PCR reaction. Cycle threshold (CT) values obtained were used to calculate gene expression 
patterns. 
 
Figure 2. 96-well format, RT2 Profiler PCR Array plate layout 
 
Data were analyzed with the GeneGlobe RT2 and miScript PCR Array Data Analysis Center 
from Qiagen. The results of the CT values were uploaded on the specified excel sheet format. 
The integrated web-based platform automatically calculates the fold-change results for gene 
expression using the equations explained in section 2.4.1. Samples were assigned to controls 
(BPH) and test group (PCa). CT values were normalized based on the 5 housekeeping/reference 
genes (ACTB, B2M, GAPDH, HPRT1 and RPLP0). The CT cut-off was set to 35. Results are 
illustrated in scatter plot, volcano plot, clustergram, tabular and heat map formats. The p values 
of fold-change were calculated based on a Student’s t-test of the replicate 2^ (- Delta CT) values 
for each gene in the BPH and PCa group. The p-value calculation used is based on parametric, 
unpaired, two-sample equal variance, two-tailed distribution.  
2.4.1. Detailed mathematical explanation of ∆∆CT data analysis method 
The data analysis web portal calculates fold-change/regulation using delta-delta CT method, in 
which delta CT is calculated between the gene of interest (GOI) and an average of reference 
genes (HKG), followed by delta-delta CT calculations [delta CT (Test Group)-delta CT (Control 
Group)]. Fold-change is then calculated using 2^ (-delta delta CT) formula.  
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Due to the inverse proportional relation between CT and the original gene expression level, 
expression levels for each gene of interest is expressed as: 
L= 2-CT 
To normalize expression levels:     
                                                                       
To determine fold-change in gene expression: 
 
The complete equation: 
 
Abbreviations: GOI, gene of interest; HKG, housekeeping gene; expt, experimental sample; 
ctrl, control sample. 
Where ∆∆CT is equal to ∆CT (expt) - ∆CT (ctrl) 
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Chapter 3.  Results 
3.1. Cohort description  
For this pilot cohort study, patients were selected from the cohort based on their self-reported 
ethnicity (Caucasians, Mixed- and African ancestry), histological confirmed diagnosis of PCa 
or BPH, PSA levels > 10 ng/ml, age and good quality of RNA extracted from prostate tissue 
samples (Table 2). The BPH patients with PSA above 10 ng/ml were selected because this 
group is the most difficult to distinguish from patients with PCa. Most patients in the BPH 
group had previous prostate biopsies to exclude PCa except for 3 patients (BPH184, BPH223 
and BPH234). Informed consent was obtained, and brief genetic counseling was provided to 
patients before enrollment. The cohort included 9 patients with PCa (2 Caucasians, 4 Mixed- 
and 3 African ancestry) and 10 patients with BPH (2 Caucasians, 5 Mixed- and 3 African 
ancestry). The PCa group has an age range of 56 to 75 years (mean 65, median 66), while the 
BPH group had a range of 60 to 76 years (mean 68, median 67). PSA levels range from 24.1 
to 5000.0 ng/ml (mean 1252.0 ng/ml, median 185.0) for the PCa group and 11.0 to 58.1 ng/mL 
(mean 25.0 ng/ml, median 22.0) for the BPH group.  
  Table 2. Cohort description 
Patient Number Agee Race PSA Diagnosis Gleason Score 
PCa037 67 MA 185.0 PCa 4+5 
PCa070 66 MA 34.0 PCa 5+4 
PCa077 71 C 24.1 PCa 4+5 
PCa108 56 A 82.6 PCa 3+4 
PCa159 75 A 5000.0 PCa 4+5 
PCa180 58 A 5000.0 PCa 5+5 
PCa183 63 MA 34.0 PCa 5+4 
PCa191 61 C 576.0 PCa 5+4 
PCa226 70 MA 332.3 PCa 5+4 
BPH148 60 MA 21.7 BPH  
BPH184 76 MA 38.8 BPH  
BPH194 67 A 12.3 BPH  
BPH215 67 MA 58.1 BPH  
BPH217 69 MA 22.7 BPH  
BPH223  65 A 20.3 BPH  
BPH234 71 C 14.1 BPH  
BPH240 63 MA 27.5 BPH  
BPH144 66 C 11.0 BPH  
BPH190 74 A 11.3 BPH  
Abbreviations:  C, Caucasian; MA, Mixed ancestry; A, African 
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3.2. RNA Isolation and cDNA synthesis 
RNA quantification was done using the NanoDrop (Thermo Scientific). RNA concentration in 
the PCa group ranging from 221.1 to 2653.8 ng/µl (mean 647.7), and 84.5 to 655.5 ng/µl (mean 
318.8) for the BPH group (Table 3).  
The A260/A280 ratio was used to determine protein contamination of nucleic acid samples. The 
ratio for a good quality RNA should be above 2. A260/A280 ratios for the PCa and BPH group 
were similar, ranging from 2 to 2.1 and A260/A230 ratios (measure of organic contamination) 
were ranging 1.7 to 2.2 (mean 1.9) for the PCa group and 0.9 to 1.9 (mean 1.6) in the BPH 
group. RNA quality was also assessed using agarose gel electrophoresis. RNA degradation was 
seen and this was because of time intervals from collecting prostate tissue specimens in theatre 
to adding RNA stabilization agent (RNAlater) in the lab, Figure 3.   
Table 3. RNA isolation results 
 
Patient Number Diagnosis 
RNA isolation 
ng/µl A260/280 A260/230 
PCa037 PCa 606.3 2.0 1.9 
PCa070 PCa 316.4 2.1 2.0 
PCa077 PCa 339.1 2.1 2.0 
PCa108 PCa 221.1 2.0 1.7 
PCa159 PCa 232.0 2.0 1.9 
PCa180 PCa 326.8 2.0 1.8 
PCa183 PCa 356.9 2.1 2.0 
PCa191 PCa 776.5 2.1 2.0 
PCa226 PCa 2653.8 2.1 2.2 
BPH148 BPH 397.9 2.1 1.8 
BPH184 BPH 357.2 2.1 1.6 
BPH194 BPH 110.3 2.1 1.1 
BPH215 BPH 336.6 2.0 1,5 
BPH217 BPH 84.5 2.0 1.9 
BPH223  BPH 345.7 2.0 1.5 
BPH234 BPH 153.0 2.0 0.9 
BPH240 BPH 655.5 2.0 1.8 
BPH144 BPH 128.0 2.0 1.6 
BPH190 BPH 410.8 2.1 1.8 
A260/280- protein contamination; A260/230- organic contamination 
 
 









3.3. PCR Array and Data Analysis 
The RT2 Profiler PCR Array include quality control to assess PCR array reproducibility, 
reverse transcription efficiency and genomic DNA contamination. For PCR array 
reproducibility, the positive PCR control of all the plates must have a CT value of 20±2 and the 
CT of two arrays should not differ with more than 2 units. All the positive PCR controls had CT 
values between 19.47 and 19.84, therefore reproducibility of the arrays was acceptable.  
The RT2 Profiler PCR Array test for genomic DNA contamination, with a CT cut-off set at 35 
all the arrays except for 4 (PCa226, CT 33.46, BPH194, CT 34.83, BPH215, CT 34.31 and 
BPH240, CT 34.96) had values above 35 indicating no genomic DNA contamination. During 
cDNA synthesis, a DNase digestion step was included to remove contaminate DNA. In further 
experiments the genomic DNA contamination can be addressed by increasing incubation time 
of the DNase digestion step.  
Housekeeping / reference genes (ACTB, B2M, GAPDH, HPRT1, and RPLP0) were used to 
normalize the data, Appendix 2. Figure 4 and Appendix 3 shows the gene expression profiles 
of the PCa and BPH groups. When considering a 2-fold change and a p value of <0.05, the 
following genes were downregulated in the PCa group compared to the BPH group ARNTL, 
CCND1, DKK3, DLC1, EGR3, FOXO1, GPX3, GSTP1, IGF1, PTEN, PTGS2, SOCS3, TIMP3, 
TNFRSF10D and ZNF185, upregulated genes included CDH1 and MKI67 but were not 






Figure 3. Agarose gel electrophoresis 
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 Figure 4. 1-D Clustergram: Gene expression patterns of the PCa and BPH group (2-fold change) 
2- 










Figure 5. Scatter Plot: Gene expression patterns in the PCa versus the BPH group (2-fold change, p value <0.05) 
 
Figure 6. Volcano Plot: Gene expression patterns in the PCa versus the BPH group (2-fold change, p value <0.05) 








At a fold-change threshold of 1.5, the following additional genes were downregulated in the 
PCa group with p values <0.05 DAXX, EGFR, RASSF1, SOX4, and TIMP2, additional 
upregulated genes were ACACA, AR, CDKN2A, ERG and FASN but were also not statistically 
significant, Figure 9, 10 and 11. Although there is no clear consensus on reporting fold-change  
thresholds, most studies use either 1.5 or 2 with p values of less than 0.05. 
 
 
Figure 7. 1-D Clustergram: illustrating the expression of genes in the PCa versus the BPH group (2-fold change, p value 
<0.05) 
Figure 8. Heat Map: Differential expression of genes in the PCa and the BPH group (2-fold change) 










Figure 9. Scatter Plot: Gene expression patterns in the PCa versus the BPH group (1.5-fold change) 
Figure 10. Volcano Plot: Gene expression patterns in the PCa versus the BPH group (1.5-fold change) 
 













Figure 11. 1-D Clustergram: illustrating the expression of genes in the PCa versus the BPH group (1.5-fold change, p 
value <0.05) 
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Chapter 4. Discussion  
4.1. Summary of findings  
To our knowledge, there are currently no studies reporting on gene expression profiling in a 
South African cohort. Our study is the first to report differential gene expressions patterns 
between PCa and BPH with PSA levels > 10ng/ml in South Africa. Other studies in the South 
African population have looked at germline mutations, tumor mutational burden and genomic-
wide associations [32, 37]. PCa is the leading cancer diagnosis amongst SA men and has been 
associated with higher mortalities compared to Europe and America. Early and accurate 
diagnosis is, therefore, imperative to institute appropriate and early treatment for patients with 
PCa.  
PSA remains the most commonly used serum-based biomarker for diagnosis and screening of 
PCa in South Africa. Its low sensitivity and specificity for PCa diagnosis has led to several 
other biomarkers being explored to try and improve its diagnostic accuracy. These biomarkers 
include serum (PHI, 4K score test), urine (PCA3, TMPRSS2-ERG fusion) and tissue-based 
biomarkers (ConfirmMDx). Only PCA3 and PHI are FDA approved, but none of these 
biomarkers are available or used for PCa diagnosis in South African men. These biomarkers 
have also not been validated for use in our unique population. This was a pilot study of 19 
patients (9 PCa and 10 BPH) from different ethnic groups in a Western Cape cohort. We 
describe a comprehensive analysis of gene expression patterns of 84 key genes commonly 
involved in PCa to differentiate between PCa and BPH in patients with PSA levels > 10ng/ml.   
The RT2 Profiler PCR Arrays were the preferred system for array-based gene expression 
profiling because of their high sensitivity, specificity and reproducibility amongst different 
users. RNA degradation was seen on agarose gel electrophoresis, this was because of the time 
intervals from collecting prostate tissue specimens to RNA stabilization with RNAlater, and an 
effort to decrease the time has been made. Opitz et al., 2010 found that degraded RNA can still 
be used to assess gene expression patterns since a higher biological variance between patients 
is observed compared to the effect of RNA degradation [38]. In our samples, RNA degradation 
was similar. To address this in future studies, an RNA stabilization agent should be added in 
theatre at the time of collection. 
Several genes were downregulated in PCa compared to BPH group, these genes include tumor 
suppressor genes PTEN, DKK3, DLC1, FOXO1 and RASSF1. These genes were similarly 
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downregulated in keeping to findings in most studies [39-41]. Phosphatase and tensin 
homologue (PTEN) is a tumor suppressor gene and its function is to inhibit cell cycle 
progression and induce a G1 arrest. Loss of expression occurs in about 40% of patients and is 
associated with adverse pathological findings, Gleason scores of 7 or higher and advanced 
pathological stages [42, 43]. This gene has also been associated with a higher risk of advanced 
disease and poor prognosis [42, 43]. Other downregulated genes in our study include, 
Glutathione S-transferase pi (GSTP1) and Prostaglandin-endoperoxide synthase 2 (PTGS2). 
GSTP1 is a cytosolic isoenzyme within the glutathione S-transferase family enzymes which is 
important in inactivation of electrophilic carcinogens by conjugation with glutathione, loss of 
this enzyme is seen in greater than 90% of patients with PCa. Silencing of this gene results in 
GSTP1 promoter methylation which is seen in early tumorigenesis and PCa progression [44, 
45]. Chronic inflammation has also been implicated in the pathogenesis of PCa. PTGS2, also 
known as cyclooxygenase-2 (COX-2) has been evaluated as a prognostic predictor marker in 
patients treated for PCa and studies have shown a better prognosis in patients with lower 
expression levels [46].  
Differences in expression were seen with Cyclin D1 (CCND1) and Early growth response 3 
(EGR3). These genes were also found to be downregulated in our study, but were reported to 
be overexpressed in other international studies. CCND1 is a critical regulator of androgen-
dependent transcription and cell cycle progression in PCa cells. This nuclear protein is involved 
in cell cycle transition from G1 (growth) to S-phase (synthesis) in both normal and neoplastic 
tissue. Overexpression of this gene has been associated with adverse pathological findings, 
high Gleason scores >7 and perineural invasion [47]. EGR3 is a member of the EGR family of 
transcription factors that play diverse functions in response to cellular stimuli, including 
growth, stress and inflammation. EGR3 is commonly upregulated in PCa and this is usually 
seen in men with less aggressive disease, while a low expression is associated with aggressive 
disease and predict relapse after PCa treatment. This can be used as a marker for diagnosis and 
prognosis of PCa [48]. In our study, most patients had high Gleason scores which could have 
contributed to the low EGR3 expression observed. 
Upregulation of the Antigen identified by monoclonal antibody Ki-67 (MKI67), Fatty acid 
synthase (FASN) and V-ets erythroblastosis virus E26 oncogene homolog (ERG) were 
similarly seen in our cohort. MKI67 and FASN overexpression are usually associated with 
progression, metastasis and a lower biochemical failure-free survival [49-53]. Androgen 
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receptor (AR) expression is higher in patients with PCa and is associated with primary PCa, 
disease progression and a lower recurrence-free survival [54]. 
E-Cadherin (CHD1) is a Ca2+ dependent homotypic cell adhesion molecule and this tumor 
suppressor gene has been reported to be underexpressed in literature and its loss is associated 
with loss of homotypic cellular adhesiveness which results in tumor cell invasion and 
metastasis [55].  
Low expression of PTEN and EGR3 and overexpression of MKI67 and FASN are seen in 
patients with adverse pathological outcomes and these have been associated with poor 
prognosis in patients diagnosed with PCa, this could explain the high mortality demonstrated 
in South African epidemiological studies. 
4.2. Limitations 
We recognize limitations in our study and these include a smaller sample size with only 9 PCa 
patients and 10 BPH patients. The sample size may not be representing a true reflection or be 
generalized to Sub-Saharan Africa as the study only included patients treated in the Western 
Cape. We could not demonstrate differences in expression profiles amongst the different ethnic 
group because of a smaller representation of the different groups. The Western Cape also 
consists of a highly heterogeneous population which could have an impact in interpreting 
results.  
Most patients in our study had high risk PCa based on Gleason scores, our cohort did not 
include patients with low risk PCa. The gene expression patterns may differ in low risk PCa, a 
follow-up study is needed to address this.  
 
4.3. Conclusion  
The aims of the study were successfully achieved. We identified a group of differentially 
expressed genes that have potential in distinguishing PCa and BPH patients with PSA values 
above 10 ng/ml. The study shows similarly differentially expressed genes as seen in 
international studies. Of note PTEN, MKI67 and FASN which are associated with poor 
prognosis. EGR3 is commonly upregulated in PCa, but in our study it was downregulated and 
this is has been associated with aggressive disease and predict relapse after PCa treatment [48]. 
Differences seen in expression profiles of CCND1 and CHD1 in our study compared to those 
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reported in other studies need to be further evaluated and their clinical significance is unknown 
in our population. A larger and more representative population study is needed to further 
evaluate the clinical significance of our findings in a South African cohort.  
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Appendices  
Appendix 1: Description of the Genes in the RT2 Profiler PCR Array for Prostate cancer 
 
Position Unigene Refseq Symbol Description 
A01 Hs.160556 NM_198834 ACACA Acetyl-CoA carboxylase alpha 
A02 Hs.525622 NM_005163 AKT1 V-akt murine thymoma viral oncogene homolog 1 
A03 Hs.158932 NM_000038 APC Adenomatous polyposis coli 
A04 Hs.76704 NM_000044 AR Androgen receptor 
A05 Hs.65734 NM_001178 ARNTL Aryl hydrocarbon receptor nuclear translocator-like 
A06 Hs.150749 NM_000633 BCL2 B-cell CLL/lymphoma 2 
A07 Hs.8417 NM_032294 CAMKK1 
Calcium/calmodulin-dependent protein kinase kinase 
1, alpha 
A08 Hs.522493 NM_015447 CAMSAP1 Calmodulin regulated spectrin-associated protein 1 
A09 Hs.141125 NM_004346 CASP3 Caspase 3, apoptosis-related cysteine peptidase 
A10 Hs.74034 NM_001753 CAV1 Caveolin 1, caveolae protein, 22kDa 
A11 Hs.212332 NM_001233 CAV2 Caveolin 2 
A12 Hs.417050 NM_003914 CCNA1 Cyclin A1 
B01 Hs.523852 NM_053056 CCND1 Cyclin D1 
B02 Hs.376071 NM_001759 CCND2 Cyclin D2 
B03 Hs.461086 NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 
B04 Hs.512599 NM_000077 CDKN2A 
Cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
B05 Hs.534667 NM_000086 CLN3 Ceroid-lipofuscinosis, neuronal 3 
B06 Hs.516646 NM_004379 CREB1 CAMP responsive element binding protein 1 
B07 Hs.336916 NM_001350 DAXX Death-domain associated protein 
B08 Hs.443960 NM_004399 DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 
B09 Hs.292156 NM_015881 DKK3 Dickkopf homolog 3 (Xenopus laevis) 
B10 Hs.134296 NM_006094 DLC1 Deleted in liver cancer 1 
B11 Hs.518299 NM_018098 ECT2 Epithelial cell transforming sequence 2 oncogene 
B12 Hs.732046 NM_000115 EDNRB Endothelin receptor type B 
C01 Hs.488293 NM_005228 EGFR Epidermal growth factor receptor 
C02 Hs.534313 NM_004430 EGR3 Early growth response 3 
C03 Hs.473819 NM_182918 ERG 
V-ets erythroblastosis virus E26 oncogene homolog 
(avian) 
C04 Hs.574240 NM_004956 ETV1 Ets variant 1 
C05 Hs.83190 NM_004104 FASN Fatty acid synthase 
C06 Hs.370666 NM_002015 FOXO1 Forkhead box O1 
C07 Hs.377894 NM_012198 GCA Grancalcin, EF-hand calcium binding protein 
C08 Hs.82963 NM_000825 GNRH1 
Gonadotropin-releasing hormone 1 (luteinizing-
releasing hormone) 
C09 Hs.386793 NM_002084 GPX3 Glutathione peroxidase 3 (plasma) 
C10 Hs.523836 NM_000852 GSTP1 Glutathione S-transferase pi 1 
C11 Hs.190783 NM_002108 HAL Histidine ammonia-lyase 
C12 Hs.643495 NM_000859 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 
D01 Hs.160562 NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C) 
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D02 Hs.607212 NM_000599 IGFBP5 Insulin-like growth factor binding protein 5 
D03 Hs.654458 NM_000600 IL6 Interleukin 6 (interferon, beta 2) 
D04 Hs.348262 NM_033495 KLHL13 Kelch-like 13 (Drosophila) 
D05 Hs.171995 NM_001648 KLK3 Kallikrein-related peptidase 3 
D06 Hs.5302 NM_006149 LGALS4 Lectin, galactoside-binding, soluble, 4 
D07 Hs.65436 NM_005576 LOXL1 Lysyl oxidase-like 1 
D08 Hs.431850 NM_002745 MAPK1 Mitogen-activated protein kinase 1 
D09 Hs.285354 NM_002382 MAX MYC associated factor X 
D10 Hs.501522 NM_002412 MGMT O-6-methylguanine-DNA methyltransferase 
D11 Hs.689823 NM_002417 MKI67 Antigen identified by monoclonal antibody Ki-67 
D12 Hs.424414 NM_002448 MSX1 Msh homeobox 1 
E01 Hs.347614 NM_012123 MTO1 
Mitochondrial translation optimization 1 homolog (S. 
cerevisiae) 
E02 Hs.437338 NM_022477 NDRG3 NDRG family member 3 
E03 Hs.618430 NM_003998 NFKB1 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 
E04 Hs.55999 NM_006167 NKX3-1 NK3 homeobox 1 
E05 Hs.155017 NM_003489 NRIP1 Nuclear receptor interacting protein 1 
E06 Hs.424312 NM_003687 PDLIM4 PDZ and LIM domain 4 
E07 Hs.459691 NM_002613 PDPK1 3-phosphoinositide dependent protein kinase-1 
E08 Hs.517543 NM_014303 PES1 
Pescadillo homolog 1, containing BRCT domain 
(zebrafish) 
E09 Hs.269128 NM_002716 PPP2R1B Protein phosphatase 2, regulatory subunit A, beta 
E10 Hs.741184 NM_006253 PRKAB1 
Protein kinase, AMP-activated, beta 1 non-catalytic 
subunit 
E11 Hs.729457 NM_000314 PTEN Phosphatase and tensin homolog 
E12 Hs.201978 NM_000962 PTGS1 
Prostaglandin-endoperoxide synthase 1 (prostaglandin 
G/H synthase and cyclooxygenase) 
F01 Hs.196384 NM_000963 PTGS2 
Prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) 
F02 Hs.654490 NM_000965 RARB Retinoic acid receptor, beta 
F03 Hs.476270 NM_007182 RASSF1 
Ras association (RalGDS/AF-6) domain family 
member 1 
F04 Hs.282901 NM_004902 RBM39 RNA binding motif protein 39 
F05 Hs.210367 NM_004719 SCAF11 SR-related CTD-associated factor 11 
F06 Hs.191346 NM_001788 SEPT7 Septin 7 
F07 Hs.213424 NM_003012 SFRP1 Secreted frizzled-related protein 1 
F08 Hs.632235 NM_001040 SHBG Sex hormone-binding globulin 
F09 Hs.444536 NM_145913 SLC5A8 Solute carrier family 5 (iodide transporter), member 8 
F10 Hs.527973 NM_003955 SOCS3 Suppressor of cytokine signaling 3 
F11 Hs.643910 NM_003107 SOX4 SRY (sex determining region Y)-box 4 
F12 Hs.592123 NM_004176 SREBF1 
Sterol regulatory element binding transcription factor 
1 
G01 Hs.515005 NM_000455 STK11 Serine/threonine kinase 11 
G02 Hs.6232 NM_014860 SUPT7L Suppressor of Ty 7 (S. cerevisiae)-like 
G03 Hs.438231 NM_006528 TFPI2 Tissue factor pathway inhibitor 2 
G04 Hs.513530 NM_015927 TGFB1I1 Transforming growth factor beta 1 induced transcript 1 
G05 Hs.633514 NM_003255 TIMP2 TIMP metallopeptidase inhibitor 2 
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G06 Hs.644633 NM_000362 TIMP3 TIMP metallopeptidase inhibitor 3 
G07 Hs.439309 NM_005656 TMPRSS2 Transmembrane protease, serine 2 
G08 Hs.213467 NM_003840 TNFRSF10D 
Tumor necrosis factor receptor superfamily, member 
10d, decoy with truncated death domain 
G09 Hs.437460 NM_000546 TP53 Tumor protein p53 
G10 Hs.631661 NM_003481 USP5 Ubiquitin specific peptidase 5 (isopeptidase T) 
G11 Hs.73793 NM_003376 VEGFA Vascular endothelial growth factor A 
G12 Hs.16622 NM_007150 ZNF185 Zinc finger protein 185 (LIM domain) 
H01 Hs.520640 NM_001101 ACTB Actin, beta 
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin 
H03 Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
H04 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 
H06 N/A SA_00105 HGDC Human Genomic DNA Contamination 
H07 N/A SA_00104 RTC Reverse Transcription Control 
H08 N/A SA_00104 RTC Reverse Transcription Control 
H09 N/A SA_00104 RTC Reverse Transcription Control 
H10 N/A SA_00103 PPC Positive PCR Control 
H11 N/A SA_00103 PPC Positive PCR Control 
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Appendix 2: House keeping genes 
Gene 
Symbol                  
  PCa108 PCa180 PCa226 PCa191 PCa159 PCa077 PCa070 PCa183 PCa037 
ACTB 23.3 23.49 18.57 23.78 25.16 19.1 19.77 25.22 22.53 
B2M 22.79 27.99 20.48 24.89 25.26 20.14 19.68 26.59 22.81 
GAPDH 23.96 26.07 19.62 24.2 26.52 20.85 21.86 27.61 22.15 
HPRT1 29.77 32.59 24.32 29.75 31.74 26.85 27.48 31.49 28.07 
RPLP0 22.01 25.82 16.83 23.18 24.67 18.83 19.2 24.28 20.14 
Average  24.37 27.19 19.96 25.16 26.67 21.15 21.60 27.04 23.14 
 
Gene 
Symbol                    
  BPH194 BPH190 BPH144 BPH240 BPH234 BPH223 BPH217 BPH215 BPH148 BPH184 
ACTB 21.89 19.44 27.76 17.12 21.64 21.71 17.63 17.85 23.75 27.65 
B2M 23.85 20.63 26.83 17.89 23.33 23.35 18.5 18.82 24.54 26.98 
GAPDH 24.23 21.88 28.67 20.18 24.52 24.53 20.49 20.57 25.45 29.01 
HPRT1 29.07 28.11 33.66 25.53 30.11 30.24 26.42 25.93 31.47 34.48 
RPLP0 23.07 20.29 26.06 18.92 23.49 23.32 19.65 19.3 23.34 27.68 















37 | P a g e  
 
Appendix 3:  Fold-change, p values and fold regulation of the Genes in the RT2 Profiler PCR 




to BPH) p-value  
Up-Down Regulation (comparing 
to BPH) 
PCa   PCa 
    Fold-Change Comments   Fold Regulation Comments 
A01 ACACA 1.52   0.070552 1.52   
A02 AKT1 0.88   0.876927 -1.13   
A03 APC 0.82 B 0.558069 -1.22 B 
A04 AR 1.76   0.098906 1.76   
A05 ARNTL 0.42   0.006391 -2.38   
A06 BCL2 0.32 A 0.205867 -3.15 A 
A07 CAMKK1 0.72 B 0.225160 -1.39 B 
A08 CAMSAP1 0.97   0.745045 -1.03   
A09 CASP3 0.97   0.795802 -1.03   
A10 CAV1 0.50   0.385606 -2.00   
A11 CAV2 0.42 A 0.134373 -2.40 A 
A12 CCNA1 0.80 B 0.388522 -1.25 B 
B01 CCND1 0.48   0.010943 -2.10   
B02 CCND2 0.42   0.149267 -2.41   
B03 CDH1 2.13   0.261015 2.13   
B04 CDKN2A 1.77 B 0.184702 1.77 B 
B05 CLN3 0.98   0.904331 -1.02   
B06 CREB1 0.88   0.545092 -1.13   
B07 DAXX 0.56   0.006940 -1.79   
B08 DDX11 0.67 B 0.217945 -1.49 B 
B09 DKK3 0.32   0.006357 -3.17   
B10 DLC1 0.50 A 0.036597 -2.02 A 
B11 ECT2 0.96 B 0.553942 -1.04 B 
B12 EDNRB 0.50   0.131846 -1.98   
C01 EGFR 0.57   0.008872 -1.75   
C02 EGR3 0.19 A 0.015944 -5.39 A 
C03 ERG 1.88 B 0.104968 1.88 B 
C04 ETV1 0.89 B 0.377959 -1.12 B 
C05 FASN 1.62   0.277313 1.62   
C06 FOXO1 0.39   0.002492 -2.58   
C07 GCA 0.87   0.625418 -1.15   
C08 GNRH1 0.60 B 0.115291 -1.67 B 
C09 GPX3 0.26   0.004700 -3.79   
C10 GSTP1 0.33   0.000877 -3.03   
C11 HAL 0.88 B 0.402755 -1.14 B 
C12 HMGCR 0.94   0.708993 -1.07   
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D01 IGF1 0.11 0.006692 -8.91
D02 IGFBP5 0.75 0.178500 -1.34
D03 IL6 0.30 B 0.050118 -3.28 B 
D04 KLHL13 0.67 B 0.662372 -1.49 B 
D05 KLK3 1.30 0.893238 1.30 
D06 LGALS4 0.68 B 0.223418 -1.47 B 
D07 LOXL1 0.57 0.419141 -1.75
D08 MAPK1 0.68 0.051867 -1.47
D09 MAX 0.69 0.061756 -1.45
D10 MGMT 0.98 0.719628 -1.02
D11 MKI67 2.38 A 0.391302 2.38 A 
D12 MSX1 1.06 B 0.479996 1.06 B 
E01 MTO1 0.74 B 0.148761 -1.35 B 
E02 NDRG3 0.92 0.645384 -1.08
E03 NFKB1 0.78 0.536526 -1.28
E04 NKX3-1 1.02 0.922412 1.02 
E05 NRIP1 0.96 0.794337 -1.05
E06 PDLIM4 0.32 0.160525 -3.08
E07 PDPK1 1.13 0.287236 1.13 
E08 PES1 0.90 0.578037 -1.11
E09 PPP2R1B 1.03 0.569266 1.03 
E10 PRKAB1 0.85 0.170024 -1.17
E11 PTEN 0.43 0.013015 -2.30
E12 PTGS1 0.25 A 0.814788 -4.04 A 
F01 PTGS2 0.37 A 0.004694 -2.70 A 
F02 RARB 0.67 0.041142 -1.48
F03 RASSF1 0.55 A 0.001482 -1.82 A 
F04 RBM39 0.84 0.257963 -1.19
F05 SCAF11 1.07 0.600118 1.07 
F06 SEPT7 0.85 0.671082 -1.18
F07 SFRP1 0.74 A 0.779941 -1.36 A 
F08 SHBG 0.79 B 0.368882 -1.27 B 
F09 SLC5A8 0.20 B 0.077062 -4.90 B 
F10 SOCS3 0.14 A 0.001280 -6.93 A 
F11 SOX4 0.54 A 0.016079 -1.84 A 
F12 SREBF1 1.00 B 0.740337 1.00 B 
G01 STK11 0.68 B 0.059605 -1.47 B 
G02 SUPT7L 0.88 0.413387 -1.13
G03 TFPI2 1.11 B 0.484275 1.11 B 
G04 TGFB1I1 0.34 A 0.082887 -2.94 A 
G05 TIMP2 0.62 0.037454 -1.63
G06 TIMP3 0.29 0.001509 -3.48
G07 TMPRSS2 1.16 0.650910 1.16 
G08 TNFRSF10D 0.43 0.000229 -2.31
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G09 TP53 0.66 0.100786 -1.52
G10 USP5 0.70 0.066257 -1.42
G11 VEGFA 0.98 0.340633 -1.02
G12 ZNF185 0.29 A 0.000050 -3.43 A 
Comments: 
A: This gene's average threshold cycle is relatively high (> 30) in either the control or the 
test sample and is reasonably low in the other sample (< 30). 
These data mean that the gene's expression is relatively low in one sample and reasonably 
detected in the other sample suggesting that the actual fold-change value is at least as large 
as the calculated and reported fold-change result. 
This fold-change result may also have greater variations if p value > 0.05, therefore, it is 
important to have a sufficient number of biological replicates to validate the result for this 
gene. 
B: This gene's average threshold cycle is relatively high (> 30), meaning that its relative 
expression level is low, in both control and test samples, and the p-value for the fold-
change is either unavailable or relatively high (p > 0.05). 
This fold-change result may also have greater variations, therefore, it is important to have 
a sufficient number of biological replicates to validate the result for this gene. 
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Appendix 4: Human research ethics committee approval 
Signature removed to avoid exposure online
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